Significant Ownership of GREAT POINT PARTNERS LLC
- Notable people
- Jeffrey R. Jay, Mr. David Kroin, Ortav Yehudai, Lillian Nordahl
- Signature - Title
- /s/ Dr. Jeffrey R. Jay, M.D - Dr. Jeffrey R. Jay, M.D - Senior Managing Member
- Location
- Greenwich, CT
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by GREAT POINT PARTNERS LLC.
Follow Filing Activity
Follow GREAT POINT PARTNERS LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from GREAT POINT PARTNERS LLC
Significant Ownership of GREAT POINT PARTNERS LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| UNCY | Unicycive Therapeutics, Inc. | Common Stock, par value $0.001 per share | 10% | $7,228,095 | 11,473,166 | Great Point Partners, LLC | 31 Dec 2024 | ||
| SCYX | SCYNEXIS, Inc. | Common Stock, par value $0.001 per share | 10% | $7,101,055 | 7,978,713 | Great Point Partners, LLC | 31 Mar 2026 | ||
| PMN | ProMIS Neurosciences Inc. | Common Shares, no par value per share | 10% | $2,790,563 | 409,648 | Great Point Partners, LLC | 31 Dec 2025 | ||
| PMN | PROMIS NEUROSCIENCES INC. | Common Shares, No Par Value per Share | 10% | $400,714 | -$2,107,681 | 954,082 | -84% | Great Point Partners, LLC | 31 Mar 2026 |
| SLGL | Sol-Gel Technologies Ltd. | Ordinary Shares, par value NIS 1.00 per share | 8.4% | $11,561,684 | 274,363 | Great Point Partners, LLC | 24 Mar 2026 | ||
| OTLK | Outlook Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5% | $4,484,400 | 2,220,000 | 0% | Great Point Partners, LLC | 30 Jun 2025 | |
| VTGN | Vistagen Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5% | $1,521,317 | 2,055,834 | 0% | Great Point Partners, LLC | 31 Dec 2025 | |
| OPTN | OPTINOSE, INC. | Common Stock, $0.001 par value per share | 4.9% | $4,789,466 | -$3,369,457 | 526,315 | -41% | Great Point Partners, LLC | 31 Mar 2025 |
| UNCY | Unicycive Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4.5% | $3,472,993 | 796,558 | 0% | Great Point Partners, LLC | 30 Sep 2025 | |
| ZURA | Zura Bio Limited | Class A Ordinary Shares | 4.4% | $25,422,058 | +$2,412,000 | 4,215,930 | +10% | Great Point Partners, LLC | 31 Mar 2026 |
| Inventiva S.A. | Ordinary shares, nominal value 0.01 Euro per share | 3.5% | 6,783,269 | -21% | Great Point Partners, LLC | 31 Dec 2025 | |||
| VOR | VOR BIOPHARMA INC. | Common Stock, $0.0001 par value per share | 3.3% | $18,578,651 | +$1,839,021 | 1,370,107 | +11% | Great Point Partners, LLC | 31 Dec 2025 |
| NGNE | NEUROGENE INC. | Common Stock, par value $0.000001 per share | 3% | $6,822,947 | 442,761 | Great Point Partners, LLC | 31 Dec 2024 | ||
| CNTX | Context Therapeutics Inc. | Common Stock | 2.4% | $5,864,860 | -$6,406,463 | 2,238,496 | -52% | Great Point Partners, LLC | 31 Mar 2026 |
Schedules 13D/G Reported by GREAT POINT PARTNERS LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.